These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36123181)

  • 1. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma.
    Kreuger IZM; Slieker RC; van Groningen T; van Doorn R
    J Invest Dermatol; 2023 Jan; 143(1):18-25.e1. PubMed ID: 36123181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
    Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunophenotypic p14 and p16 correlations with CDKN2A mutations in primary multiple and familial melanoma: An observational study.
    Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Orășanu CI; Boşoteanu M
    Medicine (Baltimore); 2023 Dec; 102(51):e36756. PubMed ID: 38134090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
    Ming Z; Lim SY; Rizos H
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
    Walker GJ; Flores JF; Glendening JM; Lin AH; Markl ID; Fountain JW
    Genes Chromosomes Cancer; 1998 Jun; 22(2):157-63. PubMed ID: 9598804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.
    Kumar R; Smeds J; Berggren P; Straume O; Rozell BL; Akslen LA; Hemminki K
    Int J Cancer; 2001 Nov; 95(6):388-93. PubMed ID: 11668523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.
    Lutful Kabir FM; DeInnocentes P; Bird AC; Bird RC
    In Vitro Cell Dev Biol Anim; 2021 May; 57(5):519-530. PubMed ID: 34014456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
    Lesueur F; de Lichy M; Barrois M; Durand G; Bombled J; Avril MF; Chompret A; Boitier F; Lenoir GM; ; Bressac-de Paillerets B; Baccard M; Bachollet B; Berthet P; Bonadona V; Bonnetblanc JM; Caron O; Chevrant-Breton J; Cuny JF; Dalle S; Delaunay M; Demange L; De Quatrebarbes J; Doré JF; Frénay M; Fricker JP; Gauthier-Villars M; Gesta P; Giraud S; Gorry P; Grange F; Green A; Huiart L; Janin N; Joly P; Kérob D; Lasset C; Leroux D; Limacher JM; Longy M; Mansard S; Marrou K; Martin-Denavit T; Mateus C; Maubec E; Olivier-Faivre L; Orlandini V; Pujol P; Sassolas B; Stoppa-Lyonnet D; Thomas L; Vabres P; Venat L; Wierzbicka E; Zattara H
    Br J Cancer; 2008 Jul; 99(2):364-70. PubMed ID: 18612309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
    Yang G; Rajadurai A; Tsao H
    J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.
    Petronzelli F; Sollima D; Coppola G; Martini-Neri ME; Neri G; Genuardi M
    Genes Chromosomes Cancer; 2001 Aug; 31(4):398-401. PubMed ID: 11433531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression.
    Tangudu NK; Buj R; Wang H; Wang J; Cole AR; Uboveja A; Fang R; Amalric A; Yang B; Chatoff A; Crispim CV; Sajjakulnukit P; Lyons MA; Cooper K; Hempel N; Lyssiotis CA; Chandran UR; Snyder NW; Aird KM
    Cancer Res Commun; 2024 May; 4(5):1174-1188. PubMed ID: 38626341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [From gene to disease; from p16 to melanoma].
    Gruis NA; Bergman W
    Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation.
    Scaini MC; Rossi E; de Siqueira Torres PL; Zullato D; Callegaro M; Casella C; Quaggio M; Agata S; Malacrida S; Chiarion-Sileni V; Vecchiato A; Alaibac M; Montagna M; Mann GJ; Menin C; D'Andrea E
    Mutat Res; 2009 Dec; 671(1-2):26-32. PubMed ID: 19712690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
    Sherburn TE; Gale JM; Ley RD
    DNA Cell Biol; 1998 Nov; 17(11):975-81. PubMed ID: 9839807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF.
    Hashemi J; Lindström MS; Asker C; Platz A; Hansson J; Wiman KG
    Cancer Lett; 2002 Jun; 180(2):211-21. PubMed ID: 12175554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
    Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
    Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.